0HB0.LAgios Pharmaceuticals, Inc.

À propos

Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of treatments within cellular metabolism and associated biological domains. Its lead product, PYRUKYND (mitapivat), serves as an activator for both healthy and various mutated forms of the pyruvate kinase (PK) enzyme, targeting the management of hemolytic anemias. Additionally, AG-946, an investigational compound, is currently undergoing Phase I clinical evaluation for hemolytic anemias and other conditions. Established in 2007, Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

www.agios.com

Statistiques clés

Capitalisation

2.22B

BPA

-7.12

Rendement dividende

0.00%

Bêta

0.59

P/B

1.32

ROE

-34.6%

Secteur

Healthcare

Industrie

Biotechnology

PDG

Brian Goff

Employés

486

Date IPO

2018-01-29

Pays

US